Biology subjects

Schaner Tooley, C. E.

Publications and source records attributed to Schaner Tooley, C. E..

3 recordsLinked to original sources

bioRxiv2026

Myosin-9b Controls Epithelial Brush Border Architecture through Motility-Dependent RhoA Signaling

Genetic variations in the MYO9B gene have been associated with Crohn's disease, celiac disease, and ulcerative colitis. These diseases have been characterized as primarily immune disorders. However, the overall molecular basis for the influence of Myo9b in these diseases remains poorly understood. Using in vivo small intestine ileum and human cell culture models, we identify a molecular function for Myo9b in the regulation of epithelial brush border microvilli. Using live-cell super-resolution microscopy, we characterize the motility of Myo9b as it moves toward enriched puncta at the tips of microvilli and visualize its direct regulation of small GTPase signaling using an active RhoA biosensor. In Myo9b knockout cells, microvilli abundance and dynamics are altered, but the cells ultimately maintain the presence of microvilli and the appropriate incorporation of microvilli specific cytoskeletal to membrane regulators such as Ezrin. Alternatively, expression of the Myo9b-S1011A disease variant as the only genetic copy in human cells results in a total loss of microvilli and Ezrin apical localization. These results indicate that Myo9b is a critical regulator of epithelial cell morphology and microvilli. Further, our data establish that the S1011A disease variant disrupts microvilli in human cells, suggesting a potential mechanistic link to its involvement in disease states.

cell biology↗

bioRxiv2021

CREB-mediated transcriptional activation of NRMT1 drives muscle differentiation

The N-terminal methyltransferase NRMT1 is an important regulator of protein-DNA interactions and plays a role in many cellular processes, including mitosis, cell cycle progression, chromatin organization, DNA damage repair, and transcriptional regulation. Accordingly, loss of NRMT1 results in both developmental pathologies and oncogenic phenotypes. Though NRMT1 plays such important and diverse roles in the cell, little is known about its own regulation. To better understand the mechanisms governing NRMT1 expression, we first identified its predominant transcriptional start site and minimal promoter region with predicted transcription factor motifs. We then used a combination of luciferase and binding assays to confirm CREB1 as the major regulator of NRMT1 transcription. We tested which conditions known to activate CREB1 also activated NRMT1 transcription, and found CREB1-mediated NRMT1 expression was increased during recovery from serum starvation and muscle cell differentiation. To determine how NRMT1 expression affects myoblast differentiation, we used CRISPR/Cas9 technology to knock out NRMT1 expression in immortalized C2C12 mouse myoblasts. C2C12 cells depleted of NRMT1 lacked Pax7 expression and were unable to proceed down the muscle differentiation pathway. Instead, they took on characteristics of C2C12 cells that have transdifferentiated into osteoblasts, including increased alkaline phosphatase and type I collagen expression and decreased proliferation. These data implicate NRMT1 as an important downstream target of CREB1 during muscle cell differentiation.

biochemistry↗

bioRxiv2020

Selective Peptidomimetic Inhibitors of NTMT1/2: Rational design, synthesis, characterization, and crystallographic studies

Protein N-terminal methyltransferases (NTMTs) methylate the -N-terminal amines of proteins starting with the canonical X-P-K/R motif. Genetic studies imply that NTMT1 regulates cell mitosis and DNA damage repair. Herein, we report the rational design and development of the first potent peptidomimetic inhibitors for NTMT1. Biochemical and co-crystallization studies manifest that BM30 (IC50 of 0.89 {+/-} 0.10 {micro}M) is a competitive inhibitor to the peptide substrate and noncompetitive to the cofactor S-adenosylmethionine. BM30 exhibits over 100-fold selectivity to NTMT1/2 among a panel of 41 methyltransferases, indicating the potential to achieve high selectivity when targeting the peptide substrate binding site of NTMT1/2. Its cell-permeable analog DC432 (IC50 of 54 {+/-} 4 nM) decreases the N-terminal methylation level of SET protein in HCT116 cells. This proof-of principle study provides valuable probes for NTMT1/2 and highlights the opportunity to develop more cell-potent inhibitors to elucidate the function of NTMTs in future.

biochemistry↗